On the other hand, the employment of small molecular inhibitors and antibodies directed against both CXCL8 and its receptor CXCR2, which is also a receptor for the chemokines CXCL1 and CXCL2, has been explored in the context of clinical trials investigating cancer therapies, thereby underscoring the potential for clinical applications 74. The gene discussed is CXCR2; the disease is cancer.